Citadel Advisors
OMED

Citadel Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Citadel Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,200
Closed -$117K – 9263
2015
Q4 		$117K Buy
+5,200
New +$107K ﹤0.01% 6523

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's OMED Position: Q4 2018 in Review

Citadel Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 18,891 shares — an estimated $40K sold.

Citadel Advisors first reported a position in OMED in Q4 2013 and held it in 10 quarters. The position peaked at $264K in Q4 2013. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Citadel Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Citadel Advisors sold 18,891 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $40K.
  • Citadel Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 10 quarters.
  • Citadel Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $264K in Q4 2013.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.